Opinion|Videos|November 15, 2024
PDE4 Inhibitor Roflumilast for AD
Key Takeaways
- The evolution of atopic dermatitis treatments emphasizes nonsteroidal options, reducing corticosteroid dependency and targeting specific inflammatory pathways.
- Nonsteroidal treatments, like PDE4 inhibitors, offer effective modulation of immune responses with a favorable side effect profile.
Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.
Advertisement
Episodes in this series
- Can you provide an overview of the current landscape of topical treatments for atopic dermatitis and how these options, specifically nonsteroidal options, have evolved over the past decade?
- What is the mechanism of action of PDE4 inhibitors, and how do they specifically target the inflammatory pathways in atopic dermatitis?
Advertisement
Related to this article
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Intismeran Plus Pembrolizumab Improves RFS in Melanoma
3
Navigating New Treatments From Alopecia to Atopic Dermatitis
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5